Silvio Inzucchi, MD, professor, Yale University School of Medicine; sectional chief of endocrinology, and medical director of Yale Diabetes Center, believes that the landscape for diabetes is constantly changing in terms of managing glucose-lowering medications.
Published in Diabetes Care, the study found that earlier detection, and importantly, initiating treatment early, can reduce cardiovascular risks.
At Patient-Centered Diabetes Care held April 16-17 in Boston, Massachusetts, Patrick J. O'Connor, MD, MA, MPH, senior clinical investigator at HealthPartners Institute for Education and Research and clinical associate professor or family medicine and community health at the University of Minnesota School of Medicine, kicked off the meeting with a discussion communicating treatment information to patients.
Children and families can benefit so much from these camps. Yes, MCOs should pay and here is why.
Coverage from the 64th Scientific Sessions of the American College of Cardiology.
Authors led by Harvard's Frank Hu, MD, write that combating diabetes worldwide requires policy solutions that recognize the societal and environmental forces that work against those who might try to pursue healthier lifestyles. Hu recently spoke at Patient-Centered Diabetes Care 2015, presented by The American Journal of Managed Care and Joslin Diabetes Center.
Coverage from the 64th Scientific Sessions of the American College of Cardiology.
Evidence-Based Diabetes Management invited the YMCA's Jonathan Lever, vice president for health strategy and innovation, to comment on his organization's involvement with the National Diabetes Prevention Program.
Coverage from the 64th Scientific Sessions of the American College of Cardiology.
Until this study, no one had reported on how the discrepancies between adult and pediatric guidelines might affect treatment for young adults.
Two new insulins marketed by Sanofi offer improved options for patients: Toujeo is longer acting than its predecessor, Lantus. Afrezza, an inhaled insulin, is gaining praise from patients, if not from Wall Street.
Risk factors associated with diabetic ketoacidosis typically do not change. Preventing DKA should focus on identification of those most at risk and educating them good self-care to avoid incidents.
Coverage from the 64th Scientific Sessions of the American College of Cardiology.
Coverage from the 64th Scientific Sessions of the American College of Cardiology.
The findings in Diabetes Care served as early confirmation of what some had feared: a bifurcated Medicaid system will lead to an American of haves and have-nots in healthcare.
An evidence review supports a proposed USPSTF recommendation to update how the healthcare system screens for prediabetes.
Major professional and advocacy groups back legislation to create access to the National Diabetes Prevention Program.
With the right support, community providers can offer an effective approach to promoting population health and preventing chronic disease.
The CDC's director of the Division of Diabetes Translation discusses the scientific evidence that supports the need for both lifestyle interventions and population-level efforts to combat type 2 diabetes in the United States.
Studies offer insights for patients with atrial fibrillation and type 2 diabetes mellitus, with more results to come.
The FDA said it had received 20 reports in the 15 months since the first of the SGLT2 inhibitor class was approved, and had continued to receive reports since that time. All drugs in the class were included in the safety communication.
What one type 1 diabetic has learned from living and coping with diabetes for 42 years.
The study, conducted by the Global eHealth Unit at the Imperial College London, has found that the majority of insulin dosing apps are unreliable and put patients at risk of getting incorrect doses of insulin. Does this demand an FDA oversight of the apps?
The prices for new hepatitis C and cancer treatments are driving the cost of prescription drugs to new highs for more Americans, according to a new report, which found that 9 of 10 patients with drug costs of $50,000 or more used specialty drugs.
